Pay in 4 interest-free payments of $6.92 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Your practice nurse can demonstrate correct subcutaneous injection technique
Ultimately, the goal is to provide holistic treatment and a satisfying patient experience
As a genetically modified herpes simplex virus-1, T-VEC has a novel mechanism of action achieved via several genomic modifications to attenuate neurovirulence, increase specificity for cancer cells, enhance antigen presentation, and stimulate the immune response by insertion of the gene for human granulocytemacrophage colony-stimulating factor (GM-CSF).1 The randomized open-label phase III trial comparing T-VEC to GM-CSF injections, known as Oncovex GM-CSF Pivotal Trial in Melanoma (OPTiM), demonstrated a superior and significant durable response rate (complete response (CR) plus partial response (PR) lasting 6 months) in the T-VEC arm (19.3% vs 1.4%) as its primary endpoint.2 3 CR and PR were achieved in 16.9% and 14.6%, respectively, and median time to CR for those who achieved it was 8.6 months
NRF2 in viral infection
Both resolutions ended the broad shortage-based legal pathway that enabled large-scale 503B outsourcing facility compounding
.webp)
US$ 21.04
US$ 21.88
US$ 27.46
US$ 24.45
US$ 20.32
US$ 20.42
US$ 29.24
US$ 20.14
US$ 20.52
US$ 23.73
